VBI Vaccines is developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology

About VBI Vaccines

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac® is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel. Learn more about VBI Vaccines >>

Vaccine Programs

Approved Vaccines
eVLP-Derived Vaccine Candidates

Dr. David Anderson, VBI's Chief Scientific Officer, discusses VBI's eVLP Platform and the company's unique approach to vaccine development.

Technology Platforms

eVLP Platform

VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely mimic the structure of viruses. VBI’s eVLP Platform provides a stable foundation that is suitable for a wide array of prophylactic and therapeutic vaccine candidates.

Learn More
LPV™ Platform

Many vaccines and biologics are highly sensitive to temperature and physical stress which may lead to a loss in potency or reduced safety, limiting protective benefits or therapeutic effects. VBI’s Lipid Particle Vaccines (“LPV”) Platform is a proprietary formulation and process designed to preserve the stability and potency of vaccines and biologics.

Learn More